Melanie Senior
Sanofi-Aventis’ rimonabant (Acomplia) was never going to fit neatly into any of the industry’s pre-defined categories. Approved in Europe in...
Welcome to In Vivo
Create an account to read this article
Already a subscriber?
The Acomplia Paradox: Primary Care Drug, Targeted Population
As Acomplia is launched across Europe, Sanofi Aventis' challenge is less about promoting the drug, than about limiting its use within the appropriate target group.